Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Foghorn Therapeutics Inc (FHTX)

Foghorn Therapeutics Inc (FHTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 285,748
  • Shares Outstanding, K 55,593
  • Annual Sales, $ 34,160 K
  • Annual Income, $ -98,430 K
  • EBIT $ -104 M
  • EBITDA $ -103 M
  • 60-Month Beta 3.10
  • Price/Sales 8.37
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 213.74% ( -4.22%)
  • Historical Volatility 68.24%
  • IV Percentile 96%
  • IV Rank 72.94%
  • IV High 278.47% on 10/21/24
  • IV Low 39.26% on 01/22/24
  • Put/Call Vol Ratio 0.75
  • Today's Volume 7
  • Volume Avg (30-Day) 20
  • Put/Call OI Ratio 0.17
  • Today's Open Interest 809
  • Open Int (30-Day) 719

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.27
  • Number of Estimates 5
  • High Estimate -0.23
  • Low Estimate -0.33
  • Prior Year -0.57
  • Growth Rate Est. (year over year) +52.63%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.57 +12.47%
on 12/16/24
8.44 -39.14%
on 12/02/24
-2.72 (-34.61%)
since 11/20/24
3-Month
4.57 +12.47%
on 12/16/24
10.17 -49.46%
on 09/23/24
-4.85 (-48.55%)
since 09/20/24
52-Week
2.70 +90.37%
on 02/05/24
10.25 -49.85%
on 09/20/24
-0.84 (-14.05%)
since 12/20/23

Most Recent Stories

More News
Foghorn Therapeutics Discontinues Development of FHD-286 for AML, Shifts Focus to Proprietary Pipeline and Collaborations

Foghorn Therapeutics halts FHD-286 development for AML, focusing on proprietary pipeline and Lilly collaboration; strong cash position until 2027.Quiver AI SummaryFoghorn Therapeutics announced the discontinuation...

FHTX : 5.14 (+3.21%)
Foghorn Therapeutics Stock Slides On Cancer Drug Development Halt, But Retail Remains Upbeat

The company stated that while clinical responses were observed, it decided to shift resources to its proprietary pipeline and collaborations with Eli Lilly.

FHTX : 5.14 (+3.21%)
Foghorn Therapeutics Provides Update on FHD-286 Clinical Development Program and Strategic Priorities

FHTX : 5.14 (+3.21%)
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences

FHTX : 5.14 (+3.21%)
Foghorn Therapeutics Provides Third Quarter 2024 Financial and Corporate Update

FHTX : 5.14 (+3.21%)
Foghorn Therapeutics Announces First Patient Dosed with First-in-Class Oral SMARCA2 Selective Inhibitor FHD-909 in a Phase 1 Trial for SMARCA4 Mutated Solid Tumors

FHTX : 5.14 (+3.21%)
Optimism Grows in the Fight Against Cancer as Breakthroughs and Funding Increase

/CNW/ -- USA News Group – Optimism is on the rise in fight against cancer, as researchers are making progress across the field of oncology. Helping to spur on...

ONCY : 0.8310 (-6.36%)
FHTX : 5.14 (+3.21%)
NRIX : 19.83 (-1.05%)
INCY : 68.84 (+2.65%)
ONC.TO : 1.19 (-9.16%)
REGN : 701.85 (-0.90%)
Flagship Pioneering Announces the Merger of Two Leading Programmable Medicine Platforms to Form Sail Biomedicines

/PRNewswire/ -- Flagship Pioneering today announced the combination of Laronde and Senda Biosciences to launch Sail Biomedicines, a company pioneering the...

DNLI : 21.45 (-0.19%)
FHTX : 5.14 (+3.21%)
MRNA : 39.39 (-0.43%)
OMGA : 0.8369 (+3.02%)
SANA : 1.6500 (+3.12%)
MCRB : 0.9155 (-0.59%)
Flagship Pioneering Appoints John Lepore as CEO-Partner and CEO of ProFound Therapeutics

/PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and ProFoundâ„¢ Therapeutics, a company pioneering the discovery of a vastly expanded...

DNLI : 21.45 (-0.19%)
FHTX : 5.14 (+3.21%)
MRNA : 39.39 (-0.43%)
OMGA : 0.8369 (+3.02%)
SANA : 1.6500 (+3.12%)
MCRB : 0.9155 (-0.59%)
Flagship Pioneering Named to Fortune's 2023 "Change the World" List

/PRNewswire/ -- Flagship Pioneering today announced it has been named to FORTUNE's 2023 "Change the World" list, an annual global ranking of companies that...

DNLI : 21.45 (-0.19%)
FHTX : 5.14 (+3.21%)
MRNA : 39.39 (-0.43%)
OMGA : 0.8369 (+3.02%)
SANA : 1.6500 (+3.12%)
MCRB : 0.9155 (-0.59%)

Business Summary

Foghorn Therapeutics Inc. engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system. Foghorn Therapeutics Inc. is based in CAMBRIDGE, Mass.

See More

Key Turning Points

3rd Resistance Point 5.72
2nd Resistance Point 5.50
1st Resistance Point 5.32
Last Price 5.14
1st Support Level 4.92
2nd Support Level 4.70
3rd Support Level 4.52

See More

52-Week High 10.25
Fibonacci 61.8% 7.37
Fibonacci 50% 6.47
Fibonacci 38.2% 5.58
Last Price 5.14
52-Week Low 2.70

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar